GALT
$3.15
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases.
Intraday
Recent News
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps
Galectin Therapeutics (NASDAQ:GALT) hosted a virtual key opinion leader (KOL) event to discuss belapectin as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, a population the speakers described as having substantial un
Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders
Key Insights Galectin Therapeutics' significant retail investors ownership suggests that the key decisions are...
Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line
Galectin Therapeutics (GALT) said Friday the US Food and Drug Administration provided a written resp
Galectin Therapeutics Inc. (GALT) Surges on Promising Belapectin Trial Data and Strong Financials
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Galectin Therapeutics Inc. is one of them. Galectin Therapeutics Inc. (NASDAQ:GALT) is a biopharmaceutical company developing therapies targeting galectin proteins, with its lead candidate, belapectin, focused on chronic liver diseases such as MASH cirrhosis […]
Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are individual investors with 54% stake, while 21% is held by insiders
NasdaqCM:GALT 1 Year Share Price vs Fair Value Explore Galectin Therapeutics's Fair Values from the Community and...